Methoxybenzoic acids and derivatives
Search Within Results
2,281
–
2,295
of
2,391
results
2,281
2,282
2,283
eMolecules 34743-49-2 | 4-Methoxy-2,6-dimethylaniline | Ambeed | MFCD03792670 | 151.209 | C9H13NO | 97.000 | COc1cc(C)c(N)c(C)c1 | 5g | 525020106
4-Methoxy-2,6-dimethylaniline | Ambeed | 34743-49-2 | MFCD03792670 | 151.209 | C9H13NO | 97.000 | COc1cc(C)c(N)c(C)c1 | 5g | 525020106
2,284
eMolecules 78191-00-1 | N-Methoxy-N-methylacetamide | Ochem Incorporation | MFCD00060098 | 103.121 | C4H9NO2 | 99.000 | CON(C)C(C)=O | 250g | 773131535
N-Methoxy-N-methylacetamide | Ochem Incorporation | 78191-00-1 | MFCD00060098 | 103.121 | C4H9NO2 | 99.000 | CON(C)C(C)=O | 250g | 773131535
2,285
Medchemexpress LLC Ro 08-2750 | 37854-59-4 | 98.01% | 270.24 | 10 MG
Ro 08-2750 is a non-peptide and reversible nerve growth factor (NGF) inhibitor that binds to NGF with an IC50 of approximately 1 μM. It selectively inhibits NGF binding to p75NTR over TRKA. Ro 08-2750 is also a selective MSI RNA-binding activity inhibitor, with an IC50 of 2.7 μM.
- Binds to the NGF dimer, potentially inducing a conformational change that prevents NGF from binding to p75NTR.
- Completely rescues cells from NGF-induced SK-N-MC 103 cell death at 10 nM.
- Increases differentiation and apoptosis in myeloid leukemia cells at 5-10 μM (8 hours).
- Inhibits survival of human AML lines and patient cells.
- Inhibits MSI2 RNA-binding and alters MSI2 gene signature.
- Inhibits leukemogenesis in a myeloid leukemia model in vivo at 13.75 mg/kg (i.p.).
- Reduces c-MYC levels and disease burden in a myeloid leukemia model.
2,286
eMolecules 2150-38-1 | Methyl 3,4-dimethoxybenzoate | Combi-Blocks | MFCD00008430 | 196.202 | C10H12O4 | 98.000 | COC(=O)c1ccc(OC)c(OC)c1 | 25g | 290688130
Methyl 3,4-dimethoxybenzoate | Combi-Blocks | 2150-38-1 | MFCD00008430 | 196.202 | C10H12O4 | 98.000 | COC(=O)c1ccc(OC)c(OC)c1 | 25g | 290688130
2,287
2,288
2,289
2,290
2,291
2,292
2,293
2,294
2,295